Novo Nordisk CEO: Wegovy Oral Tablets Reach 7 Million US Prescriptions

The headline figure is a distribution metric, not a revenue one, so the more telling signal is the CEO's claim of significant share gains over recent months — that implies the oral format is converting demand rather than merely adding to it. The commitment to reinforce the diabetes franchise suggests obesity momentum is not being treated as a substitute for the older business. Whether the oral format keeps expanding the addressable patient base, rather than shifting existing users from injectables, is the open question.